Food and Drug Administration advisory committee supports approval of antibody agent for the treatment of older Americans with acute myeloid leukemia.
Zuboy
J
J
D000208:Acute Disease; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D000079982:Gemtuzumab; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008875:Middle Aged; D014481:United States; D014486:United States Food and Drug Administration
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab